Cannabis Law Report

OCTOBER 6, 2021

Flora will conduct thorough due diligence and honor the traditional FDA and NHS route in scientific processes to ensure consistency, quality, and delivery of cannabinoids for specific disease conditions, backed by data, with an initial focus on fibromyalgia, brain health, pain, and related research. About Flora Growth Corp.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Cannabis Law Report

AUGUST 19, 2021

Such products will generate sales of £690 million ($856 million, 811 million euros) in 2021, according to the Association for the Cannabinoid Industry (ACI). Britain has experienced a “quiet cannabis revolution” that has transformed it into “the world’s second largest consumer cannabinoids market”, ACI said.

Cannabinoids 105

Cannabinoids Seed-To-Sale Clinical Trials CBD 105

Cannabis Law Report

FEBRUARY 2, 2022

– Flora’s research division, Flora Pharma, files USPTO provisional patent application on a cannabinoid-based formula. – Flora seeks approval to take their patent-pending, cannabinoid-based product through clinical trials under an EUA from INVIMA (Colombian FDA).

Cannabinoids 52

Cannabinoids Clinical Trials Events Cultivation 52

Cannabis Law Report

JULY 4, 2019

The programme aims to investigate mechanisms of action of cannabis-based medicinal products related to several clinical applications including pain and cancer, as well as characterise cannabis-based medicinal products in disease models with particular focus of chronic pain, spasticity and cancer. About EMMAC.

Cannabinoids 40

Cannabinoids Clinical Trials Chronic Pain Medicine 40

Cannabis Law Report

SEPTEMBER 3, 2019

(TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, is pleased to announce that its subsidiary MediPharm Labs Australia Pty. MediPharm Labs Australia was established in 2017.

Pharmaceutical 45

Pharmaceutical Extraction Research and Development Supply Chain 45

Cannabis Law Report

APRIL 10, 2019

MP Philippa Whitford (representing Central Ayrshire ), a doctor, called for more support for clinical trials so that doctors will be more willing to prescribe medical cannabis products: “That is quite scary for doctors, particularly as if it is an unlicensed drug, they have to sign a form to say that they accept personal liability.

Clinical Trials 51

Clinical Trials Epilepsy Medicine Research and Development 51

Cannabis Law Report

APRIL 8, 2019

The Commonwealth Parliament’s legislation is in line with a trend towards medicinal legalisation across the developed world in recognition of a growing medical consensus concerning the therapeutic role that “cannabinoids” (chemical compounds derived from plants of the genus cannabis) can play in treating disease and illness.

Medicine 71

Medicine Research and Development Business Cannabis 71